CHMP positive for Yeslty (linzagolix) to treat endometrosis
On 17 October 2024, The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Yselty
The marketing authorisation holder for this medicinal product is Theramex Ireland Limited.
The CHMP adopted a new indication to include treatment of patients with endometriosis, as follows: Yselty is indicated in adult women of reproductive age for: symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins